IMR Press / FBE / Volume 3 / Issue 4 / DOI: 10.2741/E334

Frontiers in Bioscience-Elite (FBE) is published by IMR Press from Volume 13 Issue 2 (2021). Previous articles were published by another publisher on a subscription basis, and they are hosted by IMR Press on as a courtesy and upon agreement with Frontiers in Bioscience.

The effect of pharmacological treatment on ADMA in patients with heart failure
Show Less
1 Cardiology Unit, San Camillo de Lellis Hospital, Manfredonia, Foggia, Italy
2 Biology Institute, University, G. D’Annunzio, Chieti, Italy
3 Clinical Biochemistry, Department of Biomedical Science, University, G. D’Annunzio, Chieti, Italy
4 Human Nutrition, Department of Biochemical Sciences, University, G. D’Annunzio, Chieti, Italy
5 Medical Chemistry and Molecular Biology, Department of Biological Chemistry, University of Catania, Italy
6 Department of Cardiac Surgery, IRCCS Policlinico S. Donato, Via Morandi 30, San Donato Milanese, Milan, Italy

*Author to whom correspondence should be addressed.

Academic Editor: Giovanni Li Volti

Front. Biosci. (Elite Ed) 2011, 3(4), 1310–1314;
Published: 1 June 2011
(This article belongs to the Special Issue Biochemical markers in biological fluids)

Asymmetric dimethylarginine (ADMA) plays a crucial role in the arginine-nitric oxide (NO) pathway. NO plays an important role in controlling vascular tone and regulates the contractile properties of cardiac myocytes. The purpose of this study was to investigate the effect of pharmacological treatment on asymmetrical dimethylarginine (ADMA) plasma levels in patients with acute congestive heart failure (HF). Patients with symptomatic acute congestive HF (NYHA Class III-IV) and impaired left ventricular (LV) function (ejection fraction < 40%) were included in the study. ADMA and SDMA concentrations were assessed before and after pharmacological treatment in 18 critically ill patients on the intensive care unit by high performance liquid chromatography. All patients received a complete pharmacological treatment (diuretics, digoxin, ACE-inhibitors or angiotensin receptor blockers, and nitroglicerin) for the treatment of acute congestive HF. ADMA plasma levels of critically ill patients were significantly higher after pharmacological treatment respect baseline values (pre-treatment). In critically ill patients with acute congestive HF acute renal impairment function and the modulation of NOS determine plasma ADMA/SDMA levels after therapy.

Asymmetric dimethylarginine
Heart Failure
Pulmonary Oedema
Back to top